Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sofinnova is lead investor on Crescendo's £4.5mm seed round

Executive Summary

Fragment antibody developer Crescendo Biologics has raised £4.5mm ($7.1mm) in seed financing from lead investor Sofinnova Partners, which was joined by Aitua, Avlar BioVentures, and the Rainbow Seed Fund (managed by Midven).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Transgenics
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies